

**IMPORTANT NOTICE FROM THE UNITED STATES DISTRICT COURT  
FOR THE NORTHERN DISTRICT OF CALIFORNIA**

**NOTICE OF CLASS SETTLEMENT**

If you purchased or otherwise acquired Talis common stock between February 11, 2021 and August 11, 2021, both inclusive, you may be entitled to receive a payment from a class action settlement.

**THE SETTLEMENT MAY AFFECT YOUR LEGAL RIGHTS. YOU MAY BE ELIGIBLE FOR A CASH PAYMENT. PLEASE READ THIS NOTICE CAREFULLY.**

**This Notice provides only limited information about the Settlement. For more information, please visit [www.TalisSecuritiesLitigation.com](http://www.TalisSecuritiesLitigation.com) (the “Settlement Website”) or call the Claims Administrator at (877) 331-0411.**

**Important Settlement Notice: *In re Talis Biomedical Corporation Securities Litigation*, Case No. 22-cv-00105 (N.D. Cal.) (the “Action”)**

The Parties have reached a proposed Settlement that, if approved, will resolve the Released Claims against the Released Defendant Parties on behalf of the Settlement Class.

Defendants and/or their insurance carriers have agreed to pay \$32,500,000 in total to resolve this case. This amount, plus accrued interest, and after deduction of Court-approved attorneys’ fees and Litigation Expenses (including any awards to Lead Plaintiff), Notice and Administration Costs, and Taxes, will be allocated, pursuant to the Plan of Allocation in the Long-Form Notice, among Settlement Class Members who submit valid claims.

You may be a Settlement Class Member if you purchased or otherwise acquired Talis common stock between February 11, 2021 and August 11, 2021, both inclusive.

**TO BE ELIGIBLE FOR PAYMENT, YOU MUST SUBMIT A VALID PROOF OF CLAIM ONLINE OR POSTMARKED BY MARCH 13, 2025. THE FORM IS AVAILABLE FROM THE SETTLEMENT WEBSITE, [WWW.TALISSECURITIESLITIGATION.COM](http://WWW.TALISSECURITIESLITIGATION.COM), OR BY MAIL UPON REQUEST THROUGH THE WEBSITE OR BY CALLING THE CLAIMS ADMINISTRATOR AT (877) 331-0411.**

*In re Talis Biomedical Corporation Securities Litigation*  
Claims Administrator  
c/o A.B. Data, Ltd.  
P.O. Box 173064  
Milwaukee, WI 53217

<<MAIL ID>>  
<<NAME 1>>  
<<NAME 2>>  
<<ADDRESS LINE 1>>  
<<ADDRESS LINE 2>>  
<<ADDRESS LINE 3>>  
<<ADDRESS LINE 4>>  
<<ADDRESS LINE 5>>  
<<CITY, STATE ZIP>>  
<<COUNTRY>>

For more information, please visit [www.TalisSecuritiesLitigation.com](http://www.TalisSecuritiesLitigation.com) (the “Settlement Website”) or Call the Claims Administrator at (877) 331-0411.

**The Settlement Website contains a Long-Form Notice with additional information that you should review.**

**You must comply with the Long-Form Notice's complete instructions on how to submit a Proof of Claim, exclude yourself, or object. In summary, you have three options:**

**Option 1: Submit a Proof of Claim (with further options to object to the Settlement and/or appear at the Final Approval Hearing). Proof of Claim and Release forms ("Proof of Claim") are available at [www.TalisSecuritiesLitigation.com](http://www.TalisSecuritiesLitigation.com) and must be postmarked (if mailed) or received (if submitted online) on or before March 13, 2025.**

**Option 2: Exclude yourself from the Settlement Class, as detailed in the Long-Form Notice. Exclusions must be received on or before February 21, 2025.**

**Option 3: Do nothing. You will still be bound by the Settlement and will fully release all Released Claims against the Released Defendant Parties.**

You may write to the Court if you do not like this Settlement, the Plan of Allocation and/or the request for attorneys' fees and expenses. You will still be a Member of the Settlement Class. **Objections should be sent only to the Court and must be received by the Court on or before February 21, 2025. Submitting a written objection and notice of intention to appear by February 21, 2025 allows you to speak in Court about the fairness of the Settlement, the Plan of Allocation and/or the request for attorneys' fees and expenses.** If you submit a written objection, you may (but you do not have to) attend the hearing and speak to the Court about your objection. The Court may change this date to a later date and/or time without further written notice to you.

**What is this case about? Why is there a settlement?** The Litigation alleges that the Defendants made false and misleading statements and material omissions about Talis One, the Company's molecular diagnostic platform designed to test for COVID-19 and other diseases at the point of care. Defendants deny all allegations of wrongdoing, liability, or any violation of the law whatsoever. The Parties disagree on liability and damages. Lead Plaintiff wishes to avoid the risk and delay of further litigation and secure a substantial benefit for the Settlement Class. Defendants wish to avoid the cost, distraction, burden, and uncertainty of further litigation.

**How much will I recover?** The estimated average recovery per affected share of Talis common stock is approximately \$2.05, before deduction of Court-approved fees, expenses, and costs. This is an average, and your recovery will vary based on (among other things) the number of valid claims and the size and timing of your transactions in Talis common stock.

**The Court will hold a hearing on March 14, 2025 at 10:00 a.m.** to consider whether to approve the Settlement and Co-Lead Counsel Bleichmar Fonti & Auld LLP's request for attorneys' fees not to exceed 28% of the Settlement Amount and Litigation Expenses not to exceed approximately \$1,800,000, plus interest at the same rate earned by the Settlement Fund, and an award to Lead Plaintiff of no more than \$37,500 (an average of \$0.69 per affected share of Talis common stock). You may, but are not required to, attend, and may also appear through counsel of your choice and at your own expense.

**How can I get more information?** Visit the Settlement Website at [www.TalisSecuritiesLitigation.com](http://www.TalisSecuritiesLitigation.com), contact the Claims Administrator at (877) 331-0411 or [info@TalisSecuritiesLitigation.com](mailto:info@TalisSecuritiesLitigation.com), or contact Lead Counsel at (888) 879-9418 or [TalisSettlement@bfalaw.com](mailto:TalisSettlement@bfalaw.com).

### **SPECIAL NOTICE TO NOMINEES**

Nominees who purchased or otherwise acquired Talis common stock between February 11, 2021 and August 11, 2021, both inclusive, for the beneficial interest of other Persons or entities shall, within seven (7) days after receipt of the Notice, either (1) send the Notice to such beneficial owners of such Talis common stock, or (2) send a list of the names and addresses of such beneficial owners to the Claims Administrator, in which event the Claims Administrator shall promptly mail the Notice to such beneficial owners.

If you choose the first option, you must send a statement to the Claims Administrator confirming that the mailing was made and **you must retain your mailing records for use in connection with any further notices that may be provided in the Litigation.**

If you choose the second option, the Claims Administrator will send a copy of the Notice to the beneficial owners. Upon full and timely compliance with these directions, such nominees may seek reimbursement of their reasonable expenses actually incurred by providing the Claims Administrator with proper documentation supporting the expenses for which reimbursement is sought.